Drew Lewis

423 total citations · 1 hit paper
10 papers, 276 citations indexed

About

Drew Lewis is a scholar working on Pharmacology, Molecular Medicine and Applied Microbiology and Biotechnology. According to data from OpenAlex, Drew Lewis has authored 10 papers receiving a total of 276 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pharmacology, 4 papers in Molecular Medicine and 3 papers in Applied Microbiology and Biotechnology. Recurrent topics in Drew Lewis's work include Antibiotics Pharmacokinetics and Efficacy (5 papers), Antibiotic Resistance in Bacteria (4 papers) and Antibiotic Use and Resistance (3 papers). Drew Lewis is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (5 papers), Antibiotic Resistance in Bacteria (4 papers) and Antibiotic Use and Resistance (3 papers). Drew Lewis collaborates with scholars based in United States, South Africa and Argentina. Drew Lewis's co-authors include Jeanne D. Breen, Margaret Drehobl, María Cristina De Salvo, Khurram Rana, Alita A. Miller, David Altarac, Bin Du, Lan Chen, Subasree Srinivasan and John P. O’Donnell and has published in prestigious journals such as CHEST Journal, Antimicrobial Agents and Chemotherapy and The Lancet Infectious Diseases.

In The Last Decade

Drew Lewis

10 papers receiving 258 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

2023 146 citations Keith S. Kaye, Andrew F. Shorr et al. The Lancet Infectious Diseases profile →

Peers

Countries citing papers authored by Drew Lewis

Since Specialization

Citations

This map shows the geographic impact of Drew Lewis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Drew Lewis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Drew Lewis more than expected).

Fields of papers citing papers by Drew Lewis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Drew Lewis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Drew Lewis. The network helps show where Drew Lewis may publish in the future.

Co-authorship network of co-authors of Drew Lewis

This figure shows the co-authorship network connecting the top 25 collaborators of Drew Lewis. A scholar is included among the top collaborators of Drew Lewis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Drew Lewis. Drew Lewis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK) breakdown → 2023 ·The Lancet Infectious Diseases ·Keith S. Kaye, Andrew F. Shorr, Richard G. Wunderink, Bin Du, (unknown), Khurram Rana, Alita A. Miller, Drew Lewis, John P. O’Donnell, Lan Chen, Harald H. Reinhart, Subasree Srinivasan, Robin Isaacs, David Altarac	146
2	675. Sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections: A detailed safety review from the pivotal phase 3, global, randomized, active-controlled trial (ATTACK) 2022 ·Open Forum Infectious Diseases ·Drew Lewis, Khurram Rana, (unknown), David Altarac	1
3	Sulbactam-Durlobactam Treatment Is Associated with Lower Mortality from Index Acinetobacter Infections in the Attack Phase 3 Registrational Trial 2022 ·David Altarac, Adam B. Shapiro, Khurram Rana, Drew Lewis	1
4	732. Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: Sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections 2022 ·Open Forum Infectious Diseases ·David Altarac, Alita A. Miller, Sarah M. McLeod, Adam B. Shapiro, Khurram Rana, Drew Lewis, (unknown), (unknown)	3
5	225. Efficacy and safety of sulbactam-durlobactam are consistent across regions in the global ATTACK phase 3 trial in the treatment of carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) infections 2022 ·Open Forum Infectious Diseases ·Alita A. Miller, Adam B. Shapiro, Sarah M. McLeod, Khurram Rana, Drew Lewis, David Altarac	1
6	Cost impact of hydroxocobalamin in the treatment of patients with known or suspected cyanide poisoning due to smoke inhalation from closed-space fires 2021 ·Burns ·Kafi N. Sanders, (unknown), Jennifer Stephens, (unknown), (unknown), Drew Lewis, Steven A. Kahn	4
7	Comparison of taliglucerase alfa 30U/kg and 60U/kg in treatment-naïve pediatric patients with Gaucher disease 2015 ·Molecular Genetics and Metabolism ·Ari Zimran, (unknown), Aya Abrahamov, Peter A. Cooper, (unknown), Alona Paz, Einat Brill‐Almon, Drew Lewis, (unknown), Raul Chertkoff	1
8	Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers 2010 ·Clinical Therapeutics ·John D. Davis, Frances Hackman, (unknown), (unknown), Drew Lewis, Margaret Tawadrous, James Goodrich, Grant Langdon	7
9	Single-Dose Azithromycin Microspheres vs Clarithromycin Extended Release for the Treatment of Mild-to-Moderate Community-Acquired Pneumonia in Adults 2005 ·CHEST Journal ·Margaret Drehobl, María Cristina De Salvo, Drew Lewis, Jeanne D. Breen	56
10	Novel, Single-Dose Microsphere Formulation of Azithromycin versus 7-Day Levofloxacin Therapy for Treatment of Mild to Moderate Community-Acquired Pneumonia in Adults 2005 ·Antimicrobial Agents and Chemotherapy ·(unknown), (unknown), Drew Lewis, (unknown), Jeanne D. Breen	56

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact